The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

European Commission approves Onureg for certain AML subtypes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Commission has approved Onureg (azacitidine tablets)as the first and only once-daily, frontline oral maintenance therapy in the EU for patients with a broad range of acute myeloid leukemia subtypes. 

While many patients with AML achieve remission with induction therapy, about 50% of patients relapse within one year. In the pivotal QUAZAR AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with AML, reinforcing its clinical benefit and role in the treatment paradigm for patients with this common acute leukemia.

Onureg is sponsored by Bristol Myers Squibb.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account